CSIMarket Company Name, Ticker, Competitors, else..
 

Seagen Inc   (NASDAQ: SGEN)

Seagen Inc 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

SGEN Sales vs. its Competitors Q3 2023


Comparing the current results to its competitors, Seagen Inc reported Revenue increase in the 3 quarter 2023 by 27.11 % year on year, while most of its competitors have experienced contraction in revenues by -0.76 %, achieved in the same quarter.

• List of SGEN Competitors





Revenue Growth Comparisons




Net Income Comparison

Seagen Inc , slower than the average decrease reported by the company's competitors of -27.18 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -27.18 %

<<  SGEN Stock Performance Comparisons





  

Overall company Market Share Q3 2023
Due to strong revenue growth of 27.11 % in Overall company Seagen Inc improved its market share, to approximately 2.19 %.


<<  More on SGEN Market Share.
 
*Market share is calculated based on total revenue.





Publicly Traded Peers of Seagen Inc




Sorrento Therapeutics Inc
Share Performance



0.00%
This Year
Sorrento Therapeutics Inc
Profile

Sorrento Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for various diseases, including cancer, autoimmune disorders, and pain management.

More about Sorrento Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 18.192 mill. $ 64.270 mill. $ -353.787 mill.


Autolus Therapeutics Plc
Share Performance



+19.79%
This Year
Autolus Therapeutics Plc
Profile

Autolus Therapeutics Plc is a biopharmaceutical company that focuses on the development and commercialization of next-generation engineered T-cell therapies for the treatment of cancer. Their business model is centered around utilizing innovative technology and expertise to create and advance novel therapies aimed at improving patient outcomes in oncology.

More about Autolus Therapeutics Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 596.196 mill. $ 117.390 mill. $ -280.159 mill.


Astrazeneca Plc
Share Performance



-7.70%
This Quarter
Astrazeneca Plc
Profile

AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.

More about Astrazeneca Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 127,068.700 mill. $ 73,196.000 mill. $ 12,681.000 mill.


Bicycle Therapeutics Plc
Share Performance



+2.38%
Over The Past 5 Days
Bicycle Therapeutics Plc
Profile

Bicycle Therapeutics Plc's business model is centered around the development and commercialization of novel therapeutics using its proprietary bicyclic peptide platform.

More about Bicycle Therapeutics Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 299.639 mill. $ 63.496 mill. $ -219.031 mill.


Bristol myers Squibb Company
Share Performance



+22.11%
This Quarter
Bristol myers Squibb Company
Profile

Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.

More about Bristol myers Squibb Company's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 136,780.540 mill. $ 48,482.000 mill. $ 7,271.000 mill.

75 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Seagen Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Seagen Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.